Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan vs Lansoprazole for H. pylori Eradication
NCT01505127Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2012
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vonoprazan in Helicobacter pylori infection (2 arms), sponsored by Takeda. Primary endpoint: H. pylori eradication rate 4 weeks after completion of first-line therapy. Started Jan 2012; status: completed.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT01505127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01505127.